Fibronostics

Name: Fibronostics
Address: 274 E. Eau Gallie Boulevard , #346 Indian Harbour Beach, Orlando, FL, 32937, US
Telephone: +18885521603

Fibronostics is a global diagnostics company, shaping the future of noninvasive diagnostics with artificial intelligence.

We run an in-vitro diagnostics platform that focuses on screening, progression and prognosis of metabolic diseases. Fibronostics' LIVERFASt provides early detection and monitoring for patients with NAFLD & NASH. Where the current standard for diagnosis is risky and costly with mounting evidence calling for an efficacious and cost-effective non-invasive diagnostic tool, the LIVERFASt products are easy to use with economical advantages, and have proven clinical value.

09/03/2026

Obesity, type 2 diabetes, hypertension, and dyslipidaemia are closely associated with MASLD and can increase the risk of progressive liver fibrosis.

The challenge is that liver disease may remain silent for years, even as fibrosis advances.

Recognising metabolic risk is an important first step. Assessing liver health early can help identify patients who may benefit from further evaluation, appropriate clinical management, and ongoing monitoring.

LIVERFASt™ provides a comprehensive assessment of fibrosis, inflammatory activity, and steatosis from a single routine blood sample, helping healthcare professionals see beyond metabolic risk and better understand liver health.

Because metabolic care should include liver health.

Learn more about LIVERFASt™:
https://zurl.co/xZ9gx

09/01/2026

A more complete understanding of liver health should not require a more complicated workflow.

LIVERFASt™ combines 10 commonly available biomarkers with four basic patient parameters and advanced analytics to provide:

• Fibrosis staging from F0 to F4
• Inflammatory activity grading from A0 to A3
• Steatosis grading from S0 to S3

All from a single routine blood sample.

With no specialised equipment required, LIVERFASt™ can fit into existing laboratory workflows and scale across different testing volumes.

The result is a more complete picture of liver health that can help support earlier identification, clearer risk stratification, appropriate clinical pathways, and longitudinal monitoring.

Because meaningful liver insight should be comprehensive, practical, and ready to support what happens next.

Learn more: https://zurl.co/T0XIY

08/31/2026

Steatosis is the accumulation of fat within liver cells and is often one of the earliest signs of metabolic dysfunction-associated steatotic liver disease (MASLD).

However, identifying steatosis is only one part of understanding a patient’s liver health.

Steatosis alone may not indicate advanced liver disease, but its presence, particularly alongside metabolic risk factors such as obesity, type 2 diabetes, hypertension, or dyslipidaemia, may signal the need for a more complete assessment.

This includes evaluating:
• Fibrosis, to understand the extent of liver scarring
• Inflammatory activity, to assess ongoing liver injury
• Steatosis, to determine the degree of fat accumulation

LIVERFASt™ supports this comprehensive approach by providing fibrosis staging (F0–F4), inflammatory activity grading (A0–A3), and steatosis grading (S0–S3) from a single routine blood sample.

Using 10 commonly available biomarkers and advanced analytics, LIVERFASt™ can help support earlier identification, clearer risk stratification, and more informed clinical decision-making without requiring specialised equipment.

Because understanding liver health requires more than identifying fat alone. It requires a more complete picture of disease severity and the information needed to guide what happens next.

FInd out more: https://zurl.co/V0DW0

08/28/2026

Did you know meaningful liver insights can fit into a timely, routine workflow?

Liver assessment is most valuable when clinicians can use the results to inform what happens next, without adding unnecessary delays or complexity to patient care.

With LIVERFASt™, results are available within days of sample processing, providing clinically meaningful assessment of fibrosis, steatosis, and inflammatory activity from a single routine blood sample.

No specialised equipment. A scalable laboratory workflow. A more complete picture of liver health to help support timely clinical decision-making.

Because actionable insight should not mean a complicated process.

Know more: https://zurl.co/t8cWV

08/27/2026

The future of liver care is not just about finding disease. It is about understanding how it changes over time.

As MASLD/MASH care evolves and new treatment options become available, liver assessment must evolve with it. Clinicians increasingly need tools that can support the patient journey from earlier identification and meaningful staging to ongoing assessment and monitoring.

LIVERFASt™ is designed for this changing landscape, providing biopsy-aligned assessment of fibrosis, steatosis, and inflammatory activity from a single routine blood sample.

Its blood-based approach makes assessment practical and repeatable, supporting longitudinal evaluation as a patient’s disease, metabolic health, and management plan evolve.

Because the next generation of liver care will require more than a single snapshot. It will require clearer insight across the patient journey.

Find out more: https://zurl.co/oWT3S

08/25/2026

Better liver assessment should deliver greater clinical clarity, not greater complexity.

For patients at risk of advanced fibrosis, clinical performance matters. But so does having an assessment approach that can fit practically into everyday care.

LIVERFASt™ combines high sensitivity and high negative predictive value (NPV) with a blood-based workflow, helping clinicians identify more at-risk patients while supporting efficient assessment across primary care and laboratory settings.

And the insight goes beyond a simple risk score. LIVERFASt™ provides biopsy-aligned fibrosis staging (F0–F4), together with steatosis and inflammatory activity assessment, from a single blood sample.

The result is a more complete picture of liver health, without adding specialised equipment or unnecessary complexity to existing workflows.

Because better assessment should make the next clinical decision clearer, not harder.
Find out more about LIVERFASt™ : https://zurl.co/bcSJS

08/24/2026

One key takeaway from SOLAR 2026 in San Juan, Puerto Rico: the connection between metabolic health and liver health is becoming increasingly difficult to overlook.

As obesity and metabolic disease continue to drive the growing burden of MASLD, the challenge extends beyond identifying which patients may be at risk.

Healthcare systems also need practical pathways that can support patients over time, from earlier assessment and risk stratification to follow-up, monitoring, and ongoing management.

LIVERFASt™ is designed to support this evolving approach through repeatable, blood-based assessment of fibrosis, steatosis, and inflammatory activity, helping provide clinically meaningful insights throughout the patient journey.

Thank you to everyone who connected with our team in San Juan and contributed to the conversations around building more proactive and scalable approaches to metabolic and liver health.

08/21/2026

A liver assessment result should help answer one important question: what happens next?

For patients at risk of MASLD/MASH, effective care depends on a connected clinical pathway, from identifying risk and assessing disease severity to determining whether further evaluation, referral, or ongoing monitoring is appropriate.

LIVERFASt™ supports this journey by providing biopsy-aligned fibrosis staging (F0–F4), together with steatosis and inflammatory activity assessment, giving clinicians a more complete picture of liver health from a single routine blood sample.

These clinically meaningful insights can help inform decisions across the patient pathway, whether that means further evaluation, specialist referral, longitudinal monitoring, or ongoing management.

Because the value of an assessment is not simply in the result. It is in helping clinicians determine the appropriate next step.

Learn more about LIVERFASt™ https://zurl.co/cl9k9

v

08/20/2026

Did you know advanced fibrosis can develop without obvious warning signs?

A patient may feel well, have few or no symptoms, and still have clinically significant liver fibrosis.

That is one of the challenges of MASLD. Fibrosis can progress silently for years, meaning waiting for symptoms to appear may mean missing an opportunity for earlier identification.

For patients with metabolic risk factors, proactive assessment can help uncover liver disease before it becomes clinically apparent.

LIVERFASt™ supports earlier blood-based assessment by providing biopsy-aligned fibrosis staging (F0–F4), together with steatosis and inflammatory activity, from a single routine blood sample.

Because feeling well does not always mean the liver is well.

Learn more about LIVERFASt™: https://zurl.co/kkpgP

08/18/2026

Not all non-invasive liver assessments provide the same level of clinical insight.

For patients at risk of advanced fibrosis, particularly those with MASLD and type 2 diabetes, sensitivity matters. Missing an at-risk patient at the first assessment can delay further evaluation and appropriate clinical management.

Published clinical evidence has demonstrated that LIVERFASt™ delivers higher sensitivity than FIB-4 for identifying advanced fibrosis, helping identify more patients who may otherwise be missed by traditional first-line scoring approaches.

But the LIVERFASt™ advantage goes beyond identifying risk.

Rather than providing a numerical risk score alone, LIVERFASt™ delivers biopsy-aligned fibrosis staging (F0–F4), together with steatosis (S0–S3) and inflammatory activity (A0–A3) from a single routine blood sample, providing clinicians with a more comprehensive picture of liver health.

Higher sensitivity. Clinically meaningful staging. Three liver assessments. One routine blood sample.

That is the LIVERFASt™ advantage.

Learn more about the growing clinical evidence behind LIVERFASt™:
https://zurl.co/xwvXr

Address

274 E. Eau Gallie Boulevard , #346 Indian Harbour Beach
Orlando, FL
32937

Telephone

+18885521603

Website

https://www.fibronostics.com/

Alerts

Be the first to know and let us send you an email when Fibronostics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Fibronostics:

Want your business to be the top-listed Business in Orlando?